Deanna Kroetz, PhD
Professor Emeritus
Bioengineering
School of Pharmacy

Functional genomic studies are then used to define the role of these genes and pathways in the dose-limiting toxicities. A second area of research is on the role of ABC transporters in drug resistance and physiologic function. Ongoing efforts include cryo-EM studies of MRP4 and investigation of MRP4 in resistance to immunotherapy.

• Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
  British journal of cancer 2022 Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K…
• Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.
  British journal of cancer 2021 Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K…
• Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies.
  Basic & clinical pharmacology & toxicology 2021 Chua KC, El-Haj N, Priotti J, Kroetz DL
• Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein.
  The AAPS journal 2021 Bajaj R, Chong LB, Zou L, Tsakalozou E, Ni Z, Giacomini KM, Kroetz DL
• In-depth triacylglycerol profiling using MS3 Q-Trap mass spectrometry.
  Analytica chimica acta 2021 Cabruja M, Priotti J, Domizi P, Papsdorf K, Kroetz DL, Brunet A, Contrepois K, Snyder MP
• Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel.
  Clinical and translational science 2020 Xiong C, Chua KC, Stage TB, Priotti J, Kim J, Altman-Merino A, Chan D, Saraf K, Canato Ferracini A, Fattahi F, Kroetz DL
• GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
  Clinical and translational science 2020 Ferracini AC, Lopes-Aguiar L, Lourenço GJ, Yoshida A, Lima CSP, Sarian LO, Derchain S, Kroetz DL, Mazzola PG
• Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy.
  Clinical and translational science 2020 Stage TB, Hu S, Sparreboom A, Kroetz DL
• Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
  Clinical pharmacology and therapeutics 2020 Chua KC, Xiong C, Ho C, Mushiroda T, Jiang C, Mulkey F, Lai D, Schneider BP, Rashkin SR, Witte JS, Friedman PN, Ratain MJ, McLeod HL, Rugo HS, Shulman LN, Kubo M, Owzar K, Kroetz DL
• P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.
  Clinical pharmacology and therapeutics 2020 Stage TB, Mortensen C, Khalaf S, Steffensen V, Hammer HS, Xiong C, Nielsen F, Poetz O, Svenningsen ÅF, Rodriguez-Antona C, Kroetz DL
• Reversible inhibition of efflux transporters by hydrogel microdevices.
  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2019 Levy ES, Samy KE, Lamson NG, Whitehead KA, Kroetz DL, Desai TA
• Efficient estimation of grouped survival models.
  BMC bioinformatics 2019 Li Z, Lin J, Sibley AB, Truong T, Chua KC, Jiang Y, McCarthy J, Kroetz DL, Allen A, Owzar K
• Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
  Clinical and translational science 2019 Yee SW, Giacomini MM, Shen H, Humphreys WG, Horng H, Brian W, Lai Y, Kroetz DL, Giacomini KM
• Apical Shear Stress Enhanced Organic Cation Transport in Human OCT2/MATE1-Transfected Madin-Darby Canine Kidney Cells Involves Ciliary Sensing.
  The Journal of pharmacology and experimental therapeutics 2019 Jayagopal A, Brakeman PR, Soler P, Ferrell N, Fissell W, Kroetz DL, Roy S
• A Practical First Step Using Needs Assessment and a Survey Approach to Implementing a Clinical Pharmacogenomics Consult Service.
  Journal of the American College of Clinical Pharmacy : JACCP 2018 Zakinova A, Long-Boyle JR, French D, Croci R, Wilson L, Phillips KA, Kroetz DL, Shin J, Tamraz B
• A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).
  Clinical pharmacology and therapeutics 2018 Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL
• Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
  Clinical pharmacology and therapeutics 2018 Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, Wimana Z, Gebhart G
• CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
  AIDS research and human retroviruses 2018 Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ
• Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
  Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain …
• Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity.
  Drug metabolism and disposition: the biological fate of chemicals 2018 Eclov RJ, Kim MJ, Smith R, Ahituv N, Kroetz DL
• Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.
  Pharmacogenetics and genomics 2018 Sucheston-Campbell LE, Clay-Gilmour AI, Barlow WE, Budd GT, Stram DO, Haiman CA, Sheng X, Yan L, Zirpoli G, Yao S, Jiang C, Owzar K, Hershman D, Albain KS, Hayes DF, Moore HC, Hobday TJ, Stewart JA, …
• Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.
  British journal of clinical pharmacology 2018 Stage TB, Graff M, Wong S, Rasmussen LL, Nielsen F, Pottegård A, Brøsen K, Kroetz DL, Khojasteh SC, Damkier P
• Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
  Clinical pharmacokinetics 2018 Stage TB, Bergmann TK, Kroetz DL
• ABCG2 regulatory single-nucleotide polymorphisms alter in vivo enhancer activity and expression.
  Pharmacogenetics and genomics 2017 Eclov RJ, Kim MJ, Chhibber A, Smith RP, Ahituv N, Kroetz DL
• Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.
  Pharmacology & therapeutics 2017 Li M, Kroetz DL
• Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy.
  Clinical pharmacology and therapeutics 2017 Chua KC, Kroetz DL
• In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus.
  Drug metabolism and disposition: the biological fate of chemicals 2016 Eclov RJ, Kim MJ, Smith RP, Liang X, Ahituv N, Kroetz DL
• ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
  The pharmacogenomics journal 2016 Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz DL
• Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.
  Clinical pharmacology and therapeutics 2016 Yee SW, Giacomini MM, Hsueh CH, Weitz D, Liang X, Goswami S, Kinchen JM, Coelho A, Zur AA, Mertsch K, Brian W, Kroetz DL, Giacomini KM
• Best Practices for Clinical and Translational Research and Implementation.
  Clinical and translational science 2016 Kroetz DL
• Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans.
  AIDS (London, England) 2016 Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, Mclaren PJ, Mushiroda T, Kubo M, Byakwaga H, Hunt PW, Kroetz DL
• Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev…
• Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.
  The pharmacogenomics journal 2016 Chhibber A, French CE, Yee SW, Gamazon ER, Theusch E, Qin X, Webb A, Papp AC, Wang A, Simmons CQ, Konkashbaev A, Chaudhry AS, Mitchel K, Stryke D, Ferrin TE, Weiss ST, Kroetz DL, Sadee W, Nickerson DA…
• Transforming Translation: Impact of Clinical and Translational Science.
  Clinical and translational science 2016 Wagner JA, Kroetz DL
• Multidrug resistance-associated protein 4 is a determinant of arsenite resistance.
  Oncology reports 2015 Yuan B, Yoshino Y, Fukushima H, Markova S, Takagi N, Toyoda H, Kroetz DL
• Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Komatsu M, Wheeler HE, Chung S, Low SK, Wing C, Delaney SM, Gorsic LK, Takahashi A, Kubo M, Kroetz DL, Zhang W, Nakamura Y, Dolan ME
• PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.
  Pharmacogenetics and genomics 2015 Barbarino JM, Kroetz DL, Klein TE, Altman RB
• SOX11 identified by target gene evaluation of miRNAs differentially expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients.
  Neurobiology of disease 2015 Haenisch S, Zhao Y, Chhibber A, Kaiboriboon K, Do LV, Vogelgesang S, Barbaro NM, Alldredge BK, Lowenstein DH, Cascorbi I, Kroetz DL
• Genomic architecture of pharmacological efficacy and adverse events.
  Pharmacogenomics 2014 Chhibber A, Kroetz DL, Tantisira KG, McGeachie M, Cheng C, Plenge R, Stahl E, Sadee W, Ritchie MD, Pendergrass SA
• PharmGKB summary: abacavir pathway.
  Pharmacogenetics and genomics 2014 Barbarino JM, Kroetz DL, Altman RB, Klein TE
• Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update.
  Clinical pharmacology and therapeutics 2014 Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M, Hicks JK, Wilkinson MR, Haas DW, Kroetz DL, Clinical Pharmacogenetics Implementation Consortium
• Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
  The pharmacogenomics journal 2014 Chhibber A, Mefford J, Stahl EA, Pendergrass SA, Baldwin RM, Owzar K, Li M, Winer EP, Hudis CA, Zembutsu H, Kubo M, Nakamura Y, McLeod HL, Ratain MJ, Shulman LN, Ritchie MD, Plenge RM, Witte JS, …
• Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention.
  Journal of clinical pharmacology 2014 Nicol MR, Fedoriw Y, Mathews M, Prince HM, Patterson KB, Geller E, Mollan K, Mathews S, Kroetz DL, Kashuba AD
• Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers".
  Clinical pharmacology and therapeutics 2013 Markova SM, Schwartz JB, Kroetz DL
• Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
  Pharmacogenetics and genomics 2013 Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz DL
• ABCC4 is regulated by microRNA-124a and microRNA-506.
  Biochemical pharmacology 2013 Markova SM, Kroetz DL
• Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.
  Molecular pharmacology 2013 Liu Y, Lu X, Nguyen S, Olson JL, Webb HK, Kroetz DL
• Genome-wide association studies in pharmacogenomics: successes and lessons.
  Pharmacogenetics and genomics 2013 Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, Roden DM
• Association of CYP2C9*2 with bosentan-induced liver injury.
  Clinical pharmacology and therapeutics 2013 Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, Schwartz JB, Kroetz DL
• OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.
  Pharmacogenetics and genomics 2013 Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY
• Abacavir pharmacogenetics--from initial reports to standard of care.
  Pharmacotherapy 2013 Martin MA, Kroetz DL
• The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
  Pharmacogenetics and genomics 2013 Lewis LD, Miller AA, Owzar K, Bies RR, Markova S, Jiang C, Kroetz DL, Egorin MJ, McLeod HL, Ratain MJ, Alliance for Clinical Trials in Oncology
• Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, Cancer and …
• Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
  Journal of the National Cancer Institute 2012 Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA
• A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, …
• In vitro metabolism of piperaquine is primarily mediated by CYP3A4.
  Xenobiotica; the fate of foreign compounds in biological systems 2012 Lee TM, Huang L, Johnson MK, Lizak P, Kroetz D, Aweeka F, Parikh S
• Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.
  The pharmacogenomics journal 2012 Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL
• Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor κB signaling.
  The Journal of pharmacology and experimental therapeutics 2012 Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL
• Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience.
  Cancer 2012 Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM
• Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.
  Clinical pharmacology and therapeutics 2012 Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL, Clinical Pharmacogenetics Implementation Consortium
• Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensitivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes.
  Toxicology and applied pharmacology 2011 Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz DL, Toyoda H
• Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
  Pharmacogenetics and genomics 2011 Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY,…
• Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping.
  The pharmacogenomics journal 2011 Matsson P, Yee SW, Markova S, Morrissey K, Jenkins G, Xuan J, Jorgenson E, Kroetz DL, Giacomini KM
• Functional characterization of liver enhancers that regulate drug-associated transporters.
  Clinical pharmacology and therapeutics 2011 Kim MJ, Skewes-Cox P, Fukushima H, Hesselson S, Yee SW, Ramsey LB, Nguyen L, Eshragh JL, Castro RA, Wen CC, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Relling MV, Giacomini KM, Kroetz DL, Ahituv N
• Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).
  Pharmacogenetics and genomics 2011 Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, Altman RB
• Exploiting the complexity of the genome and transcriptome using pharmacogenomics towards personalized medicine.
  Genome biology 2011 Hoppe R, Brauch H, Kroetz DL, Esteller M
• Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains.
  Protein science : a publication of the Protein Society 2010 Kelly L, Fukushima H, Karchin R, Gow JM, Chinn LW, Pieper U, Segal MR, Kroetz DL, Sali A
• Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability.
  Pharmacogenetics and genomics 2010 Ho RH, Leake BF, Kilkenny DM, Meyer Zu Schwabedissen HE, Glaeser H, Kroetz DL, Kim RB
• The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology.
  Clinical pharmacology and therapeutics 2009 Kroetz DL, Yee SW, Giacomini KM
• Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy.
  Pharmacogenomics 2009 Kroetz DL, Ahituv N, Burchard EG, Guo S, Sali A, Giacomini KM
• A survey of integral alpha-helical membrane proteins.
  Journal of structural and functional genomics 2009 Kelly L, Pieper U, Eswar N, Hays FA, Li M, Roe-Zurz Z, Kroetz DL, Giacomini KM, Stroud RM, Sali A
• Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation.
  PloS one 2009 Hesselson SE, Matsson P, Shima JE, Fukushima H, Yee SW, Kobayashi Y, Gow JM, Ha C, Ma B, Poon A, Johns SJ, Stryke D, Castro RA, Tahara H, Choi JH, Chen L, Picard N, Sjödin E, Roelofs MJ, Ferrin TE, …
• Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ
• Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila.
  The Journal of neuroscience : the official journal of the Society for Neuroscience 2009 Mayer F, Mayer N, Chinn L, Pinsonneault RL, Kroetz D, Bainton RJ
• Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
  PloS one 2008 Byakika-Tusiime J, Chinn LW, Oyugi JH, Obua C, Bangsberg DR, Kroetz DL
• Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.
  The Journal of pharmacology and experimental therapeutics 2008 Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL
• Nicotine metabolism in pregnant and nonpregnant rabbits.
  Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco 2008 Tutka P, Dempsey DA, Jacob P, Benowitz NL, Kroetz DL
• The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene.
  The Journal of pharmacology and experimental therapeutics 2008 Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL
• Substrate-dependent effects of human ABCB1 coding polymorphisms.
  The Journal of pharmacology and experimental therapeutics 2008 Gow JM, Hodges LM, Chinn LW, Kroetz DL
• The effects of ABCB1 3'-untranslated region variants on mRNA stability.
  Drug metabolism and disposition: the biological fate of chemicals 2007 Gow JM, Chinn LW, Kroetz DL
• Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein.
  The Journal of antimicrobial chemotherapy 2007 Chinn LW, Gow JM, Tse MM, Becker SL, Kroetz DL
• Adherence-resistance relationships to combination HIV antiretroviral therapy.
  Current HIV/AIDS reports 2007 Bangsberg DR, Kroetz DL, Deeks SG
• Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
  Drug metabolism and disposition: the biological fate of chemicals 2007 Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL
• Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy.
  Epilepsia 2007 Soranzo N, Kelly L, Martinian L, Burley MW, Thom M, Sali A, Kroetz DL, Goldstein DB, Sisodiya SM
• Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.
  Clinical pharmacology and therapeutics 2007 Parikh S, Ouedraogo JB, Goldstein JA, Rosenthal PJ, Kroetz DL
• Function-altering SNPs in the human multidrug transporter gene ABCB1 identified using a Saccharomyces-based assay.
  PLoS genetics 2007 Jeong H, Herskowitz I, Kroetz DL, Rine J
• The pharmacogenetics research network: from SNP discovery to clinical drug response.
  Clinical pharmacology and therapeutics 2007 Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reus V, Roden DM, Schaefer CA,…
• ABCB1 pharmacogenetics: progress, pitfalls, and promise.
  Clinical pharmacology and therapeutics 2007 Chinn LW, Kroetz DL
• Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
  Clinical pharmacology and therapeutics 2007 de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A
• Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.
  Arteriosclerosis, thrombosis, and vascular biology 2006 Ng VY, Morisseau C, Falck JR, Hammock BD, Kroetz DL
• Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Kroetz DL
• CYP4 isoform specificity in the omega-hydroxylation of phytanic acid, a potential route to elimination of the causative agent of Refsum's disease.
  The Journal of pharmacology and experimental therapeutics 2006 Xu F, Ng VY, Kroetz DL, de Montellano PR
• MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer.
  Drug metabolism and pharmacokinetics 2006 Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, Omatsu H, Koyama T, Okamura N, Miki I, Tamura T, Aoyama N, Kasuga M, Okumura K
• PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network.
  Pharmacological reviews 2006 Nguyen TD, Gow JM, Chinn LW, Kelly L, Jeong H, Huang CC, Stryke D, Kawamoto M, Johns SJ, Carlson E, Taylor T, Ferrin TE, Sali A, Giacomini KM, Kroetz DL
• PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters.
  Pharmacological reviews 2006 Shu Y, Urban TJ, Leabman MK, Fujita T, Erdman AR, Lagpacan LL, Brown C, Castro RA, Huang CC, Stryke D, Kawamoto M, Johns SJ, Taylor TR, Chan W, De La Cruz M, Carlson EJ, Ferrin TE, Brett CM, Burchard …
• PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network.
  Pharmacological reviews 2006 Badagnani I, Sorani M, Edwards RH, Brown C, Castro RA, Huang CC, Stryke D, Kawamoto M, Johns SJ, Carlson EJ, Taylor T, Chan W, De La Cruz M, Ferrin TE, Burchard EG, Herskowitz I, Kroetz DL, Giacomini …
• Induction of renal cytochrome P450 arachidonic acid epoxygenase activity by dietary gamma-linolenic acid.
  The Journal of pharmacology and experimental therapeutics 2006 Yu Z, Ng VY, Su P, Engler MM, Engler MB, Huang Y, Lin E, Kroetz DL
• Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
  Clinical pharmacology and therapeutics 2005 Andersson T, Flockhart DA, Goldstein DB, Huang SM, Kroetz DL, Milos PM, Ratain MJ, Thummel K
• Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability.
  Pharmacogenetics and genomics 2005 Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W
• Differential renal gene expression in prehypertensive and hypertensive spontaneously hypertensive rats.
  American journal of physiology. Renal physiology 2005 Seubert JM, Xu F, Graves JP, Collins JB, Sieber SO, Paules RS, Kroetz DL, Zeldin DC
• Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation.
  Annual review of pharmacology and toxicology 2005 Kroetz DL, Xu F
• Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1).
  Pharmaceutical research 2004 Pauli-Magnus C, Kroetz DL
• Vascular localization of soluble epoxide hydrolase in the human kidney.
  American journal of physiology. Renal physiology 2003 Yu Z, Davis BB, Morisseau C, Hammock BD, Olson JL, Kroetz DL, Weiss RH
• Catalytic activity and isoform-specific inhibition of rat cytochrome p450 4F enzymes.
  The Journal of pharmacology and experimental therapeutics 2003 Xu F, Falck JR, Ortiz de Montellano PR, Kroetz DL
• No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects.
  Clinical pharmacology and therapeutics 2003 Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL
• Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.
  Pharmacogenetics 2003 Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG, Pharmacogenetics of Membrane …
• Natural variation in human membrane transporter genes reveals evolutionary and functional constraints.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Leabman MK, Huang CC, DeYoung J, Carlson EJ, Taylor TR, de la Cruz M, Johns SJ, Stryke D, Kawamoto M, Urban TJ, Kroetz DL, Ferrin TE, Clark AG, Risch N, Herskowitz I, Giacomini KM, Pharmacogenetics Of…
• Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity.
  American journal of physiology. Regulatory, integrative and comparative physiology 2002 Xu F, Straub WO, Pak W, Su P, Maier KG, Yu M, Roman RJ, Ortiz De Montellano PR, Kroetz DL
• MDR1 reference sequence and reference function.
  Clinical pharmacology and therapeutics 2002 Pauli-Magnus C, Kroetz DL
• Cytochrome P450 pathways of arachidonic acid metabolism.
  Current opinion in lipidology 2002 Kroetz DL, Zeldin DC
• Covalent attachment of the heme prosthetic group in the CYP4F cytochrome P450 family.
  Biochemistry 2002 LeBrun LA, Xu F, Kroetz DL, Ortiz de Montellano PR
• Candidate gene approach for pharmacogenetic studies.
  Pharmacogenomics 2002 Ring HZ, Kroetz DL
• Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
  Circulation research 2000 Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler MM, Hammock BD, Zeldin DC, Kroetz DL
• Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney.
  Molecular pharmacology 2000 Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, Kroetz DL
• Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
  Drug metabolism and disposition: the biological fate of chemicals 2000 Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM
• Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.
  Pharmaceutical research 2000 Spiegelstein O, Kroetz DL, Levy RH, Yagen B, Hurst SI, Levi M, Haj-Yehia A, Bialer M
• Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega-hydroxylases.
  Archives of biochemistry and biophysics 2000 Hoch U, Zhang Z, Kroetz DL, Ortiz de Montellano PR
• The effects of a diet rich in docosahexaenoic acid on organ and vascular fatty acid composition in spontaneously hypertensive rats.
  Prostaglandins, leukotrienes, and essential fatty acids 1999 Engler MM, Engler MB, Kroetz DL, Boswell KD, Neeley E, Krassner SM
• Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR.
  Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1999 Engler MM, Engler MB, Goodfriend TL, Ball DL, Yu Z, Su P, Kroetz DL
• Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes.
  The Journal of biological chemistry 1998 Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T
• Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe.
  Biochemistry 1998 Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, Correia MA
• Inhibition of renal arachidonic acid omega-hydroxylase activity with ABT reduces blood pressure in the SHR.
  The American journal of physiology 1998 Su P, Kaushal KM, Kroetz DL
• Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney.
  Molecular pharmacology 1997 Kroetz DL, Huse LM, Thuresson A, Grillo MP
• Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators.
  Molecular and cellular biology 1995 Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ
• Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation.
  Biochemical pharmacology 1994 Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH
• Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms.
  Biochemistry 1993 Kroetz DL, McBride OW, Gonzalez FJ
• In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide.
  Clinical pharmacology and therapeutics 1993 Kroetz DL, Loiseau P, Guyot M, Levy RH
• Carbamazepine-valnoctamide interaction in epileptic patients: in vitro/in vivo correlation.
  Epilepsia 1993 Pisani F, Haj-Yehia A, Fazio A, Artesi C, Oteri G, Perucca E, Kroetz DL, Levy RH, Bialer M
• Measurement of in vivo microsomal epoxide hydrolase activity in white subjects.
  Clinical pharmacology and therapeutics 1993 Kroetz DL, Kerr BM, McFarland LV, Loiseau P, Wilensky AJ, Levy RH